Ionic and cellular mechanisms underlying the development of acquired Brugada syndrome in patients treated with antidepressants

Journal of Cardiovascular Electrophysiology

Volumn 23, Issue 4, 2012, Pages 423-432

  Minoura, Yoshino ^a   Di Diego, José M ^a   Barajas MartÍnez, Hector ^a   Zygmunt, Andrew C ^a   Hu, Dan ^a   Sicouri, Serge ^a   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

amitriptyline; Brugada syndrome; cardiac arrhythmias; genetics; sudden cardiac death

Indexed keywords

AMITRIPTYLINE; ISOPRENALINE; NS 5806; POTASSIUM CHANNEL STIMULATING AGENT; QUINIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; BRUGADA SYNDROME; CONTROLLED STUDY; DOG; DRUG INDUCED DISEASE; ELECTROCARDIOGRAM; EPICARDIUM; GENETIC PREDISPOSITION; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; REENTRY TACHYCARDIA; SODIUM CURRENT; ST SEGMENT ELEVATION; VOLTAGE CLAMP;

ACTION POTENTIALS; ADRENERGIC BETA-AGONISTS; AMITRIPTYLINE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BRUGADA SYNDROME; CELL LINE; DOGS; ELECTROCARDIOGRAPHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEART CONDUCTION SYSTEM; HUMANS; MALE; PATCH-CLAMP TECHNIQUES; PERFUSION; PHENOTYPE; POTASSIUM CHANNEL BLOCKERS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TACHYCARDIA, VENTRICULAR; TIME FACTORS; TRANSFECTION; VENTRICULAR FIBRILLATION;

EID: 84860115773     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2011.02196.x     Document Type: Article

References (39)

1. Sicouri S, Antzelevitch C,: Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 2008; 7: 181-194.
2. Bolognesi R, Tsialtas D, Vasini P, Conti M, Manca C,: Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Am J Cardiol 1997; 79: 242-245.
3. Rouleau F, Asfar P, Boulet S, Dube L, Dupuis JM, Alquier P, Victor J,: Transient ST segment elevation in right precordial leads induced by psychotropic drugs: Relationship to the Brugada syndrome. J Cardiovasc Electrophysiol 2001; 12: 61-65.
4. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A,: Brugada syndrome: Report of the second consensus conference. Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: 659-670.
5. Shimizu W,: Acquired forms of Brugada syndrome. In:, Antzelevitch C, ed. The Brugada Syndrome: From Bench to Bedside. Oxford, UK: Blackwell Futura, 2004, pp. 166-177.
6. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O'Brien RE, Schultze-Bahr E, Keating MT, Towbin JA, Wang Q,: Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature 1998; 392: 293-296.
7. Schulze-Bahr E, Eckardt L, Breithardt G, Seidl K, Wichter T, Wolpert C, Borggrefe M, Haverkamp W,: Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: Different incidences in familial and sporadic disease. Hum Mutat 2003; 21: 651-652.
8. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, Brugada P, Fressart V, Guerchicoff A, Harris-Kerr C, Kamakura S, Kyndt F, Koopmann TT, Miyamoto M, Pfeiffer R, Pollevick GD, Probst V, Zumhagen S, Vatta M, Towbin JA, Shimizu W, Schulze-Bahr E, Antzelevitch C, Salisbury BA, Guicheney P, Wilde AAM, Brugada R, Schott JJ, Ackerman MJ,: An international compendium of mutations in the SCN5A encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010; 7: 33-46.
9. Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, Guerchicoff A, Pfeiffer R, Oliva A, Wollnik B, Gelber P, Bonaros EP, Jr, Burashnikov E, Wu Y, Sargent JD, Schickel S, Oberheiden R, Bhatia A, Hsu LF, Haissaguerre M, Schimpf R, Borggrefe M, Wolpert C,: Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115: 442-449.
10. + current and causes inherited arrhythmias. Circulation 2007; 116: 2260-2268.
11. Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ, Demolombe S, Probst V, Anselme F, Escande D, Wiesfeld AC, Pfeufer A, Kaab S, Wichmann HE, Hasdemir C, Aizawa Y, Wilde AA, Roden DM, Bezzina CR,: Sodium channel b1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008; 118: 2260-2268.
12. Delpõn E, Cordeiro JM, Núñez L, Thomsen PEB, Guerchicoff A, Pollevick GD, Wu Y, Kanters JK, Larsen CT, Burashnikov A, Christiansen M, Antzelevitch C,: Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008; 1: 209-218.
13. Hu D, Barajas-Martinez H, Burashnikov E, Springer M, Wu Y, Varro A, Pfeiffer R, Koopmann TT, Cordeiro JM, Guerchicoff A, Pollevick GD, Antzelevitch C,: A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet 2009; 2: 270-278.
14. Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpon E, Hu D, Desai M, Borggrefe M, Haissaguerre M, Kanter R, Pollevick GD, Guerchicoff A, Laino R, Marieb M, Nademanee K, Nam GB, Robles R, Schimpf R, Stapleton DH, Viskin S, Winters S, Wolpert C, Zimmern S, Veltmann C, Antzelevitch C,: Mutations in the cardiac L-type calcium channel associated J wave sydnrome and sudden cardiac death. Heart Rhythm 2010; 7: 1872-1882.
15. Medeiros-Domingo A, Tan BH, Crotti L, Tester DJ, Eckhardt L, Cuoretti A, Kroboth SL, Song C, Zhou Q, Kopp D, Schwartz PJ, Makielski JC, Ackerman MJ,: Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm 2010; 7: 1466-1471.
16. Giudicessi JR, Ye D, Tester DJ, Crotti L, Mugione A, Nesterenko VV, Albertson RM, Antzelevitch C, Schwartz PJ, Ackerman MJ,: Transient outward current (Ito) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm 2011; 8: 1024-1032.
17. Kattygnarath D, Maugenre S, Neyroud N, Balse E, Ichai C, Denjoy I, Dilanian G, Martins RP, Fressart V, Berthet M, Schott JJ, Leenhardt A, Probst V, Le MH, Hainque B, Coulombe A, Hatem SN, Guicheney P,: MOG1: A new susceptibility gene for Brugada syndrome. Circ Cardiovasc Genet 2011; 4: 261-268.
18. Goldgran-Toledano D, Sideris G, Kevorkian JP,: Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med 2002; 346: 1591-1592.
19. Barber MJ, Starmer CF, Grant AO,: Blockade of cardiac sodium channels by amitriptyline and diphenylhydantoin. Evidence for two use-dependent binding sites. Circ Res 1991; 69: 677-696.
20. Nau C, Seaver M, Wang SY, Wang GK,: Block of human heart hH1 sodium channels by amitriptyline. J Pharmacol Exp Ther 2000; 292: 1015-1023.
21. to by antidepressant drugs. J Cardiovasc Pharmacol 1998; 32: 527-534.
22. Fish JM, Welchons DR, Kim YS, Lee SH, Ho WK, Antzelevitch C,: Dimethyl lithospermate B, an extract of danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation 2006; 113: 1393-1400.
23. Calloe K, Cordeiro JM, Di Diego JM, Hansen RS, Grunnet M, Olesen SP, Antzelevitch C,: A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res 2009; 81: 686-694.
24. Yan GX, Antzelevitch C,: Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation 1999; 100: 1660-1666.
25. Di Diego JM, Cordeiro JM, Goodrow RJ, Fish JM, Zygmunt AC, Peréz GJ, Scornik FS, Antzelevitch C,: Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002; 106: 2004-2011.
26. Antzelevitch C,: Androgens and male predominance of the Brugada syndrome phenotype. PACE 2003; 26: 1429-1431.
27. Johns JA, Anno T, Bennett PB, Snyders DJ, Hondeghem LM,: Temperature and voltage dependence of sodium channel blocking and unblocking by O-demethyl encainide in isolated guinea pig myocytes. J Cardiovasc Pharmacol 1989; 13: 826-835.
28. Akhtar M, Goldschlager NF,: Brugada electrocardiographic pattern due to tricyclic antidepressant overdose. J Electrocardiol 2006; 39: 336-339.
29. Chow BJ, Gollob M, Birnie D,: Brugada syndrome precipitated by a tricyclic antidepressant. Heart 2005; 91: 651.
30. Wang GK, Russell C, Wang SY,: State-dependent block of voltage-gated Na+ channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. Pain 2004; 110: 166-174.
31. Park KS, Kong ID, Park KC, Lee JW,: Fluoxetine inhibits L-type Ca2+ and transient outward K+ currents in rat ventricular myocytes. Yonsei Med J 1999; 40: 144-151.
32. Antzelevitch C, Yan GX,: J wave syndromes. Heart Rhythm 2010; 7: 549-558.
33. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, Brugada P, Fressart V, Guerchicoff A, Harris-Kerr C, Kamakura S, Kyndt F, Koopmann TT, Miyamoto Y, Pfeiffer R, Pollevick GD, Probst V, Zumhagen S, Vatta M, Towbin JA, Shimizu W, Schulze-Bahr E, Antzelevitch C, Salisbury BA, Guicheney P, Wilde AA, Brugada R, Schott JJ, Ackerman MJ,: An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010; 7: 33-46. Epub 2009 Oct 8.
34. Hu D, Barajas-Martinez H, Burashnikov E, Springer M, Wu Y, Varro A, Pfeiffer R, Koopmann TT, Cordeiro JM, Guerchicoff A, Pollevick GD, Antzelevitch C,: A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet 2009; 2: 270-278.
35. Vieweg WV, Wood MA,: Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics 2004; 45: 371-377.
36. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ,: Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 1999; 128: 479-485.
37. Probst V, Wilde AA, Barc J, Sacher F, Babuty D, Mabo P, Mansourati J, Le SS, Kyndt F, Le CC, Guicheney P, Gouas L, Albuisson J, Meregalli PG, Le MH, Tan HL, Schott JJ,: SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovasc Genet 2009; 2: 552-557.
38. Antzelevitch C, Fish JM,: Therapy for the Brugada syndrome. Handb Exp Pharmacol 2006; 305-330.
39. Viskin S, Wilde AA, Tan HL, Antzelevitch C, Shimizu W, Belhassen B,: Empiric quinidine therapy for asymptomatic Brugada syndrome: Time for a prospective registry. Heart Rhythm 2009; 6: 401-404.